|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial显示文摘 | Mark Sulkowski Stanislas Pol Josep Mallolas Hugo Fainboim Curtis Cooper Jihad Slim Antonio Rivero Carmen Mak Seth Thompson Anita YM Howe Larissa Wenning Peter Sklar Janice Wahl Wayne Greaves | 2013 | The Lancet Infectious Diseases2013，，7： | 1 |
| 2 | Supply-chain networks:a complex adaptive systems perspective显示文摘 | Suranaa A Kumara S Greaves Mark et al | 2005 | International Journal of Production Research2005，43，20： | 1 |
| 3 | Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes显示文摘 | Rajesh R. Singh Keyur P. Patel Mark J. Routbort Neelima Reddy Bedia Barkoh Brian Handal Rashmi Kanagal-Shamanna Wesley O. Greaves L. Jeffrey Medeiros Kenneth Aldape Rajyalakshmi Luthra | 2013 | The Journal of Molecular Diagnostics2013，，： | 1 |
| 4 | 1 Supply chain networks:a complex adaptive systems per- spective 显示文摘 | Surana Amit Kmnara Soundar Greaves Mark eta | | International Jou0，，： | 1 |
| 5 | Supply-chain networks: a complex adaptive systems perspective 显示文摘 | Amit Surana Soundar Kumara Mark Greaves | 2005 | International Journal of Production Research2005，43，20： | 1 |
| 6 | Trimethylaminuria , the use of choline as an aid to diagnosis显示文摘 | MARKS R GREAVES M PROTTEY C | 1977 | BritishJournal of Dermatology1977，96，4： | 1 |
| 7 | Supply-chain networks :a complex adaptive systems perspective显示文摘 | Amit Surana Soundar Kumara Mark Greaves Usha Nandini Raghavan | 2005 | International Journal of Production Research2005，43，20： | 1 |
| 8 | Semantics and the crowd显示文摘One of the principal scientific challenges that drives my group is to understand the character of formal knowledge on the Web. By formal | Mark GREAVES | 2012 | Journal of Zhejiang University-Science C(Computers and Electronics)2012，13，4： | 0 |
| 9 | Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection显示文摘AIM To evaluate efficacy/safety of hepatitis C virus(HCV) protease inhibitor boceprevir with pegylated interferon(PEG-IFN) alfa and weight-based ribavirin(RBV) in a phase 3 trial. METHODS A prospective, multicenter, phase 3, open-label, singlearm study of PEG-IFN alfa, weight-based RBV, and boceprevir, with a PEG-IFN/RBV lead-in phase was performed. The HCV/human immunodeficiency virus coinfected study population included treatment na?ve(TN) and treatment experienced(TE) patients. Treatment duration ranged from 28 to 48 wk dependent upon response-guided criteria. All patients had HCV Genotype 1 with a viral load > 10000 IU/ml. Compensated cirrhosis was allowed. Sample size was determined to establish superiority to historical(PEG-IFN plus RBV) rates in sustained viral response(SVR). RESULTS A total of 257 enrolled participants were analyzed(135 TN and 122 TE). In the TN group, 81.5% were male and 54.1% were black. In the TE group, 76.2% were male and 47.5% were white. Overall SVR12 rates(HCV RNA < lower limit of quantification, target not detected, target not detected) were 35.6% in TN and 30.3% in TE. Response rates at SVR24 were 28% in TN and 10% in TE, and exceeded those in historical controls. The highest rate was observed in TN non-cirrhotic participants(36.8% and the lowest in TE cirrhotics(26.3%). Cirrhotic TN participants had a 27.8% SVR12 rate and 32.1% of TE non-cirrhotics achieved SVR12. Significantly lower response rates were observed among black participants; in the TE, SVR12 was 39.7% in white participants but only 13.2% of black subjects(P = 0.002). Among the TN, SVR12 was 42.1% among whites and 27.4% among blacks(P = 0.09). CONCLUSION The trial met its hypothesis of improved SVR compared to historical controls but overall SVR rates were low. All-oral HCV treatments will mitigate these difficulties. | Kenneth E Sherman Minhee Kang Richard Sterling Triin Umbleja Kristen Marks Jennifer J Kiser Beverly Alston-Smith Wayne Greaves Adeel A Butt 无 | 2017 | World Journal of Hepatology2017，9，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员